Drug discovery
Lechleiter bets history will repeat for Lilly
January 16, 2012
J.K. WallEli Lilly and Co. CEO John Lechleiter keeps pouring more money into research and development, even as analysts note the payoff
of such spending has dropped off 70 percent in the last decade.
MoreEndocyte stays course despite being battered by investors
December 31, 2011
J.K. WallAfter spending most of 2011 as a Wall Street darling, the year ended ugly for Endocyte Inc. But CEO Ron Ellis thinks the West
Lafayette-based drug developer is in better position than ever.
MoreLilly losing dominance in diabetes treatment
December 31, 2011
J.K. WallEli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses
on other products that have begun to sap the drugmaker's sales.
MoreEndocyte shares plunge on clinical trial results
December 13, 2011
J.K. WallShares of Endocyte Inc. plummeted more than 60 percent Tuesday morning after clinical trial results showed the company’s
experimental ovarian cancer drug led to shorter survival times than treatment with a standard cancer drug.
MoreLilly shares rise on possibility for Alzheimer’s drug
December 7, 2011
Bloomberg NewsEli Lilly and Co. stock rose to a one-month high Tuesday after an analyst said the possible success of the company’s
experimental Alzheimer’s drug could double the share price.
MorePotential Lilly drug doubles good cholesterol
November 15, 2011
Bloomberg NewsEli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck &
Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.
MorePotential Effient rival shows promise in study
November 14, 2011
Bloomberg NewsA study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could
give the companies entry to a $1 billion-plus market where Eli Lilly already competes.
MoreLilly, Amylin agree to end diabetes partnership
November 8, 2011
Bloomberg News, Associated PressAmylin Pharmaceuticals Inc. and Eli Lilly and Co. have agreed to end a decade-long diabetes partnership to resolve litigation.
Amylin will make an upfront payment of $250 million to Lilly and future revenue-sharing payments of $1.2 billion plus interest.
MoreLilly fights view that fate hinges on Alzheimer's drug
October 29, 2011
Greg AndrewsAnalysts have eyes on trial data for drug that could be a game-changer for the company.
MoreLilly wins European approval for new use of Alimta
October 28, 2011
J.K. WallIndianapolis-based drugmaker can now market lung cancer drug as a continuation maintenance therapy, potentially boosting sales
after recent loss of patent on bestseller Zyprexa.
MoreQ&A
October 17, 2011
J.K. WallSherry Keramidas, who earned her doctorate in neuroscience and physiological psychology from Purdue University,
is executive director of the Maryland-based Regulatory Affairs Professionals Society, which is holding its annual conference
Oct. 22-26 at the Indiana Convention Center.
MoreHealth regulatory leaders ready to flock to city
September 14, 2011
IBJ StaffThe top event for regulatory professionals in the health care industry is headed to Indianapolis next month. The annual conference
of the Regulatory Affairs Professionals Society, or RAPS, is expected to draw thousands of members representing 120 companies
and organizations.
MoreFDA gets new report on Lilly diabetes drug
September 12, 2011
Associated PressDrugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Monday that patients taking their potential once-weekly
diabetes treatment, Bydureon, saw a significant improvement in cardiovascular risk factors.
MoreEli Lilly's Elanco unit blossoming at just the right time
July 30, 2011
Greg AndrewsAn investment firm projects that the Elanco animal-health business will generate sales of nearly $2 billion by 2012 and surpass
$3 billion by 2018.
MoreLechleiter: German drug pricing creates 'uncertainty' for Lilly
July 11, 2011
Bloomberg NewsEli Lilly & Co. CEO John C. Lechleiter said Germany’s overhaul of drug pricing lacked transparency and the new policy
creates “uncertainty” for the company’s business planning.
MoreTiming good for 2-in-1 biotech drugs
July 5, 2011
J.K. WallEli Lilly and Co.’s foray into combination drugs is well-timed because the company could take advantage of some the
world’s most successful biotech medicines, which are about to see their patents expire.
MoreR&D spending soars above value of new drugs
July 5, 2011
J.K. WallTo understand the depths of the pharmaceutical industry’s recent struggles, consider this: The industry has been spending
$57 billion more per year on research and development than the value of the products it has been launching. That’s a
problem.
MoreLilly plans 10 drugs in final-stage trials by year's end
June 30, 2011
Bloomberg NewsLilly has 33 drugs in the second and third stages of clinical trials, including medicines for cancer, diabetes and Alzheimer’s
disease, up from seven in 2005, the Indianapolis-based company said Thursday.
MoreLilly diabetes pill recommended for EU approval
June 24, 2011
Bloomberg NewsEli Lilly and Co. and Boehringer Ingelheim GmbH’s Trajenta medicine for Type 2 diabetes has been recommended for approval
in Europe, putting the drug on track to enter the region’s market this year.
MoreLilly CEO: Immigration, tax laws slow innovation
June 23, 2011
Bloomberg NewsThe U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly
& Co. CEO John Lechleiter plans to tell a technology conference Thursday.
MoreAmylin sues Lilly over drug development deal
May 16, 2011
Associated PressAmylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking
their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim to develop and sell
a competing product.
MoreLilly drug to detect Alzheimer’s criticized by consumer group
May 11, 2011
Bloomberg NewsEli Lilly and Co.’s Amyvid, an experimental imaging agent to detect signs of Alzheimer’s disease in the brain,
shouldn’t be approved because of unreliable study results, a consumer-advocacy group said.
MoreTwo wins to bring Lilly modest sales
May 9, 2011
J.K. WallFinally, some new revenue. Eli Lilly and Co. will enjoy modest new sales later this year after U.S. regulators approved a
new diabetes drug developed by a partner company, and another company nears approval on a drug that will produce royalties
for the Indianapolis-based drugmaker.
MoreFDA OKs new diabetes pill from Lilly, Boehringer
May 2, 2011
IBJ Staff and Associated PressThe Food and Drug Administration says it has approved a new diabetes pill from Boehringer Ingelheim and Eli Lilly for patients
who can't control their blood sugar with older medicines.
MoreLilly teams with Medtronic on Parkinson's treatment
April 26, 2011
J.K. WallEli Lilly and Co. plans to use an implantable drug-delivery system made by Medtronic Inc. to precisely target patients'
brains with an experimental drug for Parkinson’s disease.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
IBJ Featured Advertisers
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Members must realize if you stop paying your dues you will lose. Why else would your employer honor the rtw bill. Before you take this step think about what you may be giving up in the long run. Very little of your dues money goes to any dem candidate. YOu will never know how much your republican employer gives his party with money he could be paying the employee. Who will step up and demand better wages or benefits if you have no representation. Union is the way for a better life. Our carpenter union offers a 4 year apprenticeship and 2 year degree from Ivy Tech all paid for with union dues . This is a great opportunity for kids who cant afford schooling after high school. The same opportunity is there for any person,any age, either sex to provide a better living for their family. Pension, anuity, health insurance all for your dues. How is this a bad choice.
The FDIC is funded by assessments paid by banks, not taxpayers. That is not to say that bank customers don't ultimately pay the cost because, in the end, banks don't survive if they don't make profits.
SCB Bank's failure is expected to cost the government $33.9 million,dont you mean middle class another bailout our government has no money
Diogenes, the company did not call "pro-life" statements inflammatory. The IBJ article used the words "pro life."
All, the company did, is what it should do which is apologize profusely for offending people with a program that offered statements that support an infamous apartheid proponent, Dr. Verwoerd, suggest that sometimes rape is justified, and quote Biblical text to people, not looking for it.
If this is what you think is "insanity" then more companies need to behave insanely.
I totally disagree with $45mil being given to the state Attorney General's office. That money is a waste. All of the money should go to help the homeowners & the people who were foreclosed on. Why such a big percentage to state govt? They'll get to start another agency staffed with people who have new-found power & don't care about the people they serve. As soon as the program was announced, I knew the states would end up with a huge chunk of the money for themselves that would just be squandered. Or maybe Mitch Daniels will just happen to "find" another big chunk of money that was "posted in the wrong section of the state's books."